Ri-Qiang Liao

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 992 citations

Medicine, Immunology, Oncology +17

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen et al. · Journal of Clinical Oncology · 2019 · 267 citations

Medicine, Oncology, Pharmacology +15

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Wei Gao et al. · Cancer Discovery · 2022 · 222 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan et al. · Lung Cancer · 2012 · 164 citations

Medicine, Oncology, Pharmacology +17

Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy

Si-Pei Wu, Ri-Qiang Liao, Hai‐Yan Tu et al. · Journal of Thoracic Oncology · 2017 · 153 citations

Life Sciences, Immunology, Oncology +14